Bioprojet

Societe Civile Bioprojet

Other

Bioproject

Societe Civile Bioproject

Bioprojet Pharma

Xavier Ligneau

Jean-Charles Schwartz

Jeanne-Marie Lecomte

Philippe Robert

Marc Capet

Nicolas Levoin

Isabelle Berrebi-Bertrand

Olivier Labeeuw

Thierry Calmels

Jean-Michel Arrang

Xavier Billot

Stéphane Krief

Holger Stark

Walter Schunack

Monique Garbarg

Charon R Ganellin

Denis Danvy

David Perrin

Sigurd Elz

Fabien Leurquin

Antonio Guglietta

Manuel M Raga

Olivia Poupardin-Olivier

Juan Sallares

Marta Guerrero

Jeanne Marie Lecomte

Jean Charles Schwartz

Isabelle Bertrand

Laurent Landais

Charon Ganellin

Marc Maury

Katja Purand

Wasyl Tertiux

Michael C O Krause

Sadek Bassem

Charon Robbin Ganellin

Nadia Pelloux-Leon

Athmani Salah

Annette Huls

Walter G Schunack

Agnes Quemener

Hulger Stark

Walter G Schunacx

Jeanne-Marie Lecounte

Laurent François Gérard Landais

Jean-Stëphane Julien

Reidemeister Sybille

Isabelle Berrebi Bertrand

Jean-Stéphane Julien

Stephane Krief

Charon Robin Ganellin

Jean-Stephane Julien

Laurent Francois Landais

The present application concerns novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands.

Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands

Disclosed are combinations of a H3 antagonist and an antidepressant, which exhibit a synergistic wake promoting activity.

Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof

Novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands are disclosed.

The present invention relates to combinations of a H3 antagonist and an antidepressant, which exhibit a synergistic wake promoting activity.

The present invention concerns a novel combination of adrenalin with an antidepressant and its use as a pharmaceutical composition for the treatment of shocks. A method is also provided for treating a subject in need thereof by administering the combination of adrenaline with an antidepressant. The pharmaceutical composition is to be administered by injection.

Combination of adrenalin with an antidepressant for use in the treatment of shocks

The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhea.

Form of administration of enkephalinase inhibitor

The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.

6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands

The present invention concerns novel (aza)benzhydryl ether derivatives which exhibit H4-receptor binding activity. The present invention also concerns their process of preparation and their therapeutical uses.

(Aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications

Benzazole derivatives as histamine H4 receptor ligands

The present patent application concerns new ligands of the H4-receptor of formula (I), their process of preparation and their therapeutic use. 

The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent. 

[object Object]

A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2&#x3b8;) at 11.2&#xb0;, 19.9&#xb0;, 20.7&#xb0; and 34.1&#xb0;&#xb1;0.2&#xb0; is administered to a patient in need thereof.

Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine

The invention relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.

Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine

The present patent application concerns compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a mono or bicyclic saturated nitrogen-containing ring; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease.

Histamine H3-receptor ligands and their therapeutic applications

The present patent application concerns new compounds of formula (I) with Rand Rtaken together with the nitrogen atom to which they are attached, form a saturated nitrogen-containing ring, A is a saturated C1-4 alkylene and B a C3-4 alkylene or alkenylene chain; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease. 

Growing community of inventors

Saint Gregoire, France

Xavier Ligneau